Nykaa stock nears 52-week high: Will the rally continue? Here's what brokerages say
Recent product launches, improving financials, and optimistic guidance have piqued investor interest—leaving one big question: can the rally sustain?
Nykaa's stock closed at ₹ 209.85 recently, marking a 2.3 percent gain for June—its fourth consecutive monthly advance. It rose 4.5 percent in May, 8.5 percent in April, and surged 12.8 percent in March. This consistent climb follows a 6 percent dip in February, offset by a modest 3 percent gain in January. The stock's recent strength comes as it rebounds from a 52-week low of ₹ 154.90 touched in March 2025.
The momentum also coincides with the launch of Nykaa Now, the company's new quick commerce platform for beauty products. Already operational in seven cities, Nykaa Now promises order deliveries within 30 to 120 minutes, positioning Nykaa competitively in the fast-delivery beauty space.
Looking ahead, Nykaa has outlined a bold expansion plan, targeting three to four times growth over the next five years. The management expects the fashion business to achieve EBITDA breakeven by FY26, with margins expanding to mid-single digits by FY28. For its core Beauty and Personal Care (BPC) vertical, Nykaa is aiming for steady-state EBITDA margins of around 10 percent.
The second half of FY26 will also see several marquee product launches, aimed at bolstering growth further across both BPC and fashion segments.
Several brokerages have weighed in on Nykaa's latest roadmap, offering cautious optimism.
Nomura sees Nykaa's BPC segment well-positioned to deliver 27 percent and 25 percent revenue growth in FY26 and FY27, respectively, citing its strong premium beauty presence. However, it remains conservative on the fashion business, labeling management's expectations as 'ambitious,' especially given the 'high level of competition.' The brokerage forecasts fashion margins to stay negative at -7 percent by FY27. Nomura has maintained a 'Neutral' rating with a DCF-based target of ₹ 216, calling the current valuation of around 5x FY26 EV/sales fair.
JM Financial sounded more upbeat, particularly highlighting faster-than-expected breakeven guidance in fashion. It noted Nykaa's aggressive growth in BPC and fashion, along with strong traction in its eB2B Superstore vertical. The brokerage expects stable contribution margins in BPC and EBITDA margin expansion driven by operating leverage. It retained a 'Buy' rating with a March 2026 target of ₹ 250.
Nuvama Institutional Equities echoed similar sentiments, focusing on the company's long-term potential and profitability roadmap. The brokerage said Nykaa's BPC segment is expected to grow at a mid-20 percent CAGR between FY25 and FY30, while the fashion division should reach EBITDA breakeven in FY26. Nuvama also noted the potential of Nykaa's private label vertical 'House of Nykaa,' which targets a GMV of ₹ 6,000 crore by FY30. It expects further improvements in profitability from lower losses in fashion and B2B operations and retained a 'Buy' rating with a DCF-based target price of ₹ 235.
Disclaimer: The views and recommendations made above are those of individual analysts or broking companies, and not of Mint. We advise investors to check with certified experts before making any investment decisions.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
2 hours ago
- Economic Times
Dr Reddy's, Sun Pharma and other pharma stocks fall up to 3% as Trump threatens 25% tariff on India
Shares of major Indian pharmaceutical companies slumped as much as 3% on July 31, after U.S. President Donald Trump declared a 25% tariff and additional penalties on Indian goods, citing India's ongoing trade with Russia. The move rattled investor sentiment, particularly in export-focused sectors such as pharma, which have so far been exempt from reciprocal tariff action under the U.S.'s Section 232 trade investigations. ADVERTISEMENT The Nifty Pharma index dropped as much as 1.5% during the day. Shares of Ipca Laboratories led the decline, falling as much as 3.2% to Rs 1,480.10, while Zydus Lifesciences was down 3% to Rs 965.20. Dr Reddy's Laboratories, Biocon, Cipla and Sun Pharma also lost between 1% and 3%. India's pharmaceutical sector, which currently enjoys zero-tariff access to the U.S. for its generic drugs, may be directly impacted if the 25% tariff is applied to drug exports as well. 'The U.S. administration's sudden announcement of a 25% tariff on all Indian imports starting August 1 seems to have injected some volatility across the Indian markets, affecting export-driven sectors to the US, like pharma, and auto makers, among others,' analysts at Nomura said.'Sectors under ongoing Section 232 investigation (pharmaceuticals, semiconductors & electronics, among others) are currently exempt from reciprocal tariffs, while existing Section 232 tariffs will apply on steel & aluminum (50%) and autos – finished and parts (25%),' Nomura said. ADVERTISEMENT Utsav Verma, Head of Research, Institutional Equities at Choice Broking, said the latest development is likely to trigger a reassessment of investor positioning across key export sectors. 'In response to President Trump's recent imposition of a 25% tariff and penalties on Indian goods, investors will reassess their strategies with a mix of caution and optimism,' he said, adding that 'sectors like textiles, pharmaceuticals, and automotive components—key Indian exports—are likely to be most impacted and may see reduced investor interest in the short term.'Still, Verma struck a note of guarded optimism about the broader trade outlook. 'Recent progress in trade negotiations suggests a constructive path forward, and we believe that the trade deal will eventually follow provided both nations show the necessary political will,' he said. 'Many investors expect the tariff rate to eventually settle around 15%, paving the way for renewed confidence and stronger trade ties.' ADVERTISEMENT 'In the short term, the market will try to shed off its complacency. We do not expect a huge knee-jerk reaction but a range-bound market focused on ongoing earnings,' Verma the new tariffs extend to pharmaceuticals, analysts are of the view that Indian drugmakers may be forced to consider options such as passing the additional cost on to consumers, removing low-margin products from the U.S. market, or manufacturing within the U.S., though the latter would likely erode the cost advantage generic producers currently enjoy. ADVERTISEMENT Sun Pharma, which was among the stocks under pressure on Thursday, is set to report its quarterly results later in the day. India's top generic drug exporters including Dr. Reddy's Laboratories, Divi's Laboratories, Cipla, Aurobindo Pharma, Lupin and Biocon will likely remain in focus as markets assess the full implications of the U.S. administration's latest tariff salvo. ADVERTISEMENT Also read | Trump's tariffs threaten to deepen $248 billion India stock rout (Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times) (You can now subscribe to our ETMarkets WhatsApp channel)
Economic Times
4 hours ago
- Economic Times
Picture abhi baki hai: Why Sensex, Nifty are down but not crashing after Trump's 25% tariff bombshell
US President Donald Trump's bombshell announcement of a brutal 25% tariff on Indian goods imports, the highest among Asian nations, and coupled with mysterious "additional penalties" for Russia ties, sent shockwaves through sectors from textiles to pharmaceuticals. The Sensex and Nifty tumbled around 1% each in the morning but quickly recovered most of the losses with battle-hardened investors already sharpening their knives to buy the dip as tariffs are expected to be negotiated lower next month. ADVERTISEMENT The tariff assault, effective August 1st, marks India as Trump's primary Asian target with rates that dwarf those slapped on Vietnam (20%), Indonesia, and the Philippines (19% each). Market experts point out to the fact that not only is the negotiation road still open, but FIIs have already priced in most of the tariff pain as they have already withdrawn around Rs 25,000 crore from the stock market in the last 8 days of non-stop selling. 'The announced higher reciprocal tariff rate of 25%, however, may be temporary, and might settle down lower. Unlike other countries, India is in the process of securing a detailed trade deal with the US. Most of the other countries have secured very rough-cut deals, with some agreements largely verbal. Indian government sources had previously suggested that an 'interim' deal was meant to be part of a more comprehensive trade deal that would take until end-2025 to agree upon,' Nomura's Sonal Varma said. While stating that India has undertaken a more sensible approach to prioritise detailed evaluation of any trade deal instead of agreeing on a hurried deal based on a tight deadline, Varma said these negotiations will take time and, very importantly, are still ongoing.'The US trade delegation is set to visit India at the end of August as part of this process. Hence, the elevated tariffs announced by the US are unlikely to be permanent, in our view, although the best-case outcome would be tariffs in the 15-20% range,' the brokerage firm said. Geojit's Dr. VK Vijayakumar also agreed, saying while the tariff is very bad news for Indian exports and thereby on the growth prospects of the Indian economy in the short run, it is the typical Trumpian strategy to get better deals from India in other areas and finally settle at a tariff rate around 20% or less. ADVERTISEMENT "Nifty is unlikely to go below the support level of 24500. Investors can buy the dip focusing on domestic consumption themes, particularly segments like leading private sector banking names, telecom, capital goods, cement, hotels and select autos which have done well in Q1,' he tariff tsunami crashed hardest into exporters across auto components, select capital goods, chemicals, pharma, refiners, solar and textiles. Nuvama sounded a more ominous note about the real danger lurking beneath: "The higher tariffs on India (versus expectations) could potentially weigh on capital flows." ADVERTISEMENT "FII flows have now become critical in shaping market outcomes amid heavy promoter selling and slowing DII flows,' it said, adding that rupee depreciation could help IT and it could potentially outperform given the now low relative economist lead Madhavi Arora delivered perhaps the most reassuring assessment: "The tariff will have little impact on India's 2HFY26E earnings recovery trajectory, as high-weightage sectors such as financials, consumption, and technology are unaffected." ADVERTISEMENT Her verdict on the 25% rate: "We believe the 25%+ regime is the worst-case scenario and the final bilateral deal could be reached with a lower tariff ... .In any case, a meaningful correction is an opportunity to buy the market with consumer discretionary and industrials as the key sectors." With Indian government sources previously suggesting an 'interim' deal as part of a comprehensive trade agreement lasting until end-2025, the current tariff rates appear more like opening shots in a prolonged negotiation rather than final settlements. (You can now subscribe to our ETMarkets WhatsApp channel)
Time of India
4 hours ago
- Time of India
Dr Reddy's, Sun Pharma and other pharma stocks fall up to 3% as Trump threatens 25% tariff on India
Shares of major Indian pharmaceutical companies slumped as much as 3% on July 31, after U.S. President Donald Trump declared a 25% tariff and additional penalties on Indian goods, citing India's ongoing trade with Russia. The move rattled investor sentiment , particularly in export-focused sectors such as pharma, which have so far been exempt from reciprocal tariff action under the U.S.'s Section 232 trade investigations. The Nifty Pharma index dropped as much as 1.5% during the day. Shares of Ipca Laboratories led the decline, falling as much as 3.2% to Rs 1,480.10, while Zydus Lifesciences was down 3% to Rs 965.20. Dr Reddy's Laboratories , Biocon , Cipla and Sun Pharma also lost between 1% and 3%. Explore courses from Top Institutes in Please select course: Select a Course Category Product Management Technology Operations Management Data Science Management Project Management Leadership Healthcare Design Thinking Artificial Intelligence MCA Public Policy Others Degree MBA PGDM CXO Skills you'll gain: Creating Effective Product Roadmap User Research & Translating it to Product Design Key Metrics via Product Analytics Hand-On Projects Using Cutting Edge Tools Duration: 12 Weeks Indian School of Business ISB Product Management Starts on May 14, 2024 Get Details Skills you'll gain: Product Strategy & Roadmapping User-Centric Product Design Agile Product Development Market Analysis & Product Launch Product Strategy & Roadmapping User-Centric Product Design Agile Product Development Market Analysis & Product Launch Duration: 24 Weeks Indian School of Business Professional Certificate in Product Management Starts on Jun 26, 2024 Get Details Skills you'll gain: Product Strategy & Roadmapping User-Centric Product Design Agile Product Development Market Analysis & Product Launch Duration: 24 Weeks Indian School of Business Professional Certificate in Product Management Starts on Jun 26, 2024 Get Details India's pharmaceutical sector, which currently enjoys zero-tariff access to the U.S. for its generic drugs , may be directly impacted if the 25% tariff is applied to drug exports as well. 'The U.S. administration's sudden announcement of a 25% tariff on all Indian imports starting August 1 seems to have injected some volatility across the Indian markets, affecting export-driven sectors to the US, like pharma, and auto makers, among others,' analysts at Nomura said. 'Sectors under ongoing Section 232 investigation (pharmaceuticals, semiconductors & electronics, among others) are currently exempt from reciprocal tariffs, while existing Section 232 tariffs will apply on steel & aluminum (50%) and autos – finished and parts (25%),' Nomura said. Live Events Strategic recalibration ahead Utsav Verma, Head of Research, Institutional Equities at Choice Broking, said the latest development is likely to trigger a reassessment of investor positioning across key export sectors. 'In response to President Trump's recent imposition of a 25% tariff and penalties on Indian goods, investors will reassess their strategies with a mix of caution and optimism,' he said, adding that 'sectors like textiles, pharmaceuticals, and automotive components—key Indian exports—are likely to be most impacted and may see reduced investor interest in the short term.' Still, Verma struck a note of guarded optimism about the broader trade outlook. 'Recent progress in trade negotiations suggests a constructive path forward, and we believe that the trade deal will eventually follow provided both nations show the necessary political will,' he said. 'Many investors expect the tariff rate to eventually settle around 15%, paving the way for renewed confidence and stronger trade ties.' 'In the short term, the market will try to shed off its complacency. We do not expect a huge knee-jerk reaction but a range-bound market focused on ongoing earnings,' Verma said. Limited options for Indian pharma Should the new tariffs extend to pharmaceuticals, analysts are of the view that Indian drugmakers may be forced to consider options such as passing the additional cost on to consumers, removing low-margin products from the U.S. market, or manufacturing within the U.S., though the latter would likely erode the cost advantage generic producers currently enjoy. Sun Pharma, which was among the stocks under pressure on Thursday, is set to report its quarterly results later in the day. India's top generic drug exporters including Dr. Reddy's Laboratories, Divi's Laboratories , Cipla, Aurobindo Pharma , Lupin and Biocon will likely remain in focus as markets assess the full implications of the U.S. administration's latest tariff salvo. Also read | Trump's tariffs threaten to deepen $248 billion India stock rout ( Disclaimer : Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)
